Vaxcyte (PCVX) Other Non-Current Liabilities (2019 - 2025)
Vaxcyte (PCVX) posted quarterly Other Non-Current Liabilities of $100000.0 for Q4 2025, little changed year-over-year from $100000.0 in Q4 2024, and little changed quarter-over-quarter from $100000.0 in Q4 2024.
Powered by 
Analysis
Vaxcyte (PCVX) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Vaxcyte (PCVX) has reported Other Non-Current Liabilities for 7 consecutive years, with $100000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed 0.0% year-over-year to $100000.0; the TTM figure through Dec 2025 stood at $100000.0 (changed 0.0% YoY), while the FY2025 annual figure was $100000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities held at $100000.0 in Q4 2025 per PCVX's latest filing, from $100000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $103000.0 in Q1 2021 and bottomed at $2000.0 in Q3 2023.
- Historically, Other Non-Current Liabilities has averaged $68769.2 across 5 years, with a median of $93000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 97.75% — and 2025, when it changed 0.0%.
- Vaxcyte's Other Non-Current Liabilities stood at $96000.0 in 2021, then slumped by 90.62% to $9000.0 in 2022, then tumbled by 77.78% to $2000.0 in 2023, then jumped by 4900.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
- Business Quant data shows PCVX's Other Non-Current Liabilities at $100000.0 in Q4 2025, $100000.0 in Q4 2024, and $2000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 100,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 7,000.00 |
| Dec 31, 2022 | 9,000.00 |
| Sep 30, 2022 | 89,000.00 |
| Jun 30, 2022 | 92,000.00 |
| Mar 31, 2022 | 93,000.00 |
| Dec 31, 2021 | 96,000.00 |
| Sep 30, 2021 | 98,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 103,000.00 |
| Dec 31, 2020 | 112,000.00 |
| Sep 30, 2020 | 128,000.00 |
| Jun 30, 2020 | 136,000.00 |
| Dec 31, 2019 | 242,000.00 |